Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961709 · ClinicalTrials.gov registry record · Phase 2
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
A Phase 2 study of Colon Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT05961709: Recruiting Phase 2 study of Colon Cancer, sponsored by M.D. Anderson Cancer Center.
NCT05961709 is a Phase 2 study of Colon Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05961709, a Phase 2 study of Colon Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
To learn if cemiplimab can help to control dMMR colon cancer.
Conditions Studied
Interventions
- DRUG Cemiplimab
Study Locations (5)
Arizona
- Banner - MD Anderson Cancer - Gilbert
Florida
- Baptist - MD Anderson Cancer Center - Jacksonville
Louisiana
- Ochsner - New Orleans
New Jersey
- Cooper University Medical Center - Camden
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
What NCT05961709 shows while recruiting
NCT05961709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cemiplimab is the first listed.
NCT05961709 lists 5 locations in 5 states (Arizona, Florida, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05961709 about?
NCT05961709 is a clinical study titled "The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer". To learn if cemiplimab can help to control dMMR colon cancer.
What is the current status of trial NCT05961709?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-05-20. Estimated completion is 2028-04-30.
What conditions does trial NCT05961709 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT05961709?
The interventions under investigation include: Cemiplimab (DRUG).
Who is sponsoring clinical trial NCT05961709?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05961709 being conducted?
This trial has 5 study locations across Arizona, Florida, Louisiana, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05961709's enrollment target sits among peer trials
50 68th of 97 higher than 27 of 97 other Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI